The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Takeda
Stock and Other Ownership Interests - Takeda

Updated results from first-in-human phase 1 dose-escalation trial of TAK-102, a GPC3-targeted armored CAR T cells, in patients with advanced solid tumors.
 
Takako Eguchi Nakajima
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Nobelpharma; Ono Pharmaceutical; PAREXEL INTERNATIONAL; Pfizer; Pfizer; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Rebirthel (Inst); Thyas Co. Ltd (Inst)
Research Funding - Abbvie (Inst); Chugai Pharma (Inst); KBBM (Inst); Lilly Japan (Inst); Novartis (Inst); Otsuka (Inst); Taiho Pharmaceutical (Inst); Taisho Pharmaceutical Holdings (Inst); Takeda (Inst); Zymeworks (Inst)
 
Yasutoshi Kuboki
Honoraria - Lilly Japan; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Abbvie; Amgen; Boehringer Ingelheim; Incyte; Janssen Oncology; Takeda
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Carna Biosciences (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Janssen Oncology (Inst); Jiangsu Hengrui Pharmaceuticals (Inst); Lilly (Inst); Merck Serono (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Amgen; Chugai Pharma; Incyte
 
Masaru Fukahori
No Relationships to Disclose
 
Yutaka Shimazu
No Relationships to Disclose
 
Shunsuke Kondo
Honoraria - Chugai Pharma; Eisai; Sanofi
Speakers' Bureau - Chugai Pharma; Eisai
Research Funding - Abbvie; AZD; Boehringer Ingelheim; Chugai Pharma; Eisai; Incyte; Lilly
 
Yuki Katsuya
No Relationships to Disclose
 
Masafumi Ikeda
Honoraria - Abbvie; AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Eisai; Fujifilm; Guardant Health; Incyte; Lilly Japan; MSD; Nihonkayaku; Nobelpharma; Novartis; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical; Taisho Pharmaceutical Holdings; Takeda; Teijin Pharma; Yakult Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Boston Scientific; Chugai Pharma; Eisai; Guardant Health; MSD; Novartis; Roche; SERVIER
Research Funding - AstraZeneca (Inst); Bayer Yakuhin (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chiome Bioscience (Inst); Chugai Pharma (Inst); Delta-Fly Pharma (Inst); Eisai (Inst); InVitae (Inst); J-Pharma (Inst); Lilly Japan (Inst); Merck (Inst); Merus NV (Inst); MSD (Inst); Nihon Servier (Inst); Nobelpharma (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Rakuten Medical Japan (Inst); Syneos Health (Inst)
 
Tomoyuki Satake
Honoraria - AstraZeneca
Research Funding - Nihon Servier (Inst)
 
Hideaki Kagehara
No Relationships to Disclose
 
Takenori Akaike
Employment - Takeda Pharmaceutical Company Limited Cure Bioscience
 
Aman P Singh
Employment - Takeda
Stock and Other Ownership Interests - Takeda
 
Kondala Atkuri
Employment - Takeda
Stock and Other Ownership Interests - Takeda
Research Funding - Takeda
Patents, Royalties, Other Intellectual Property - Takeda
Travel, Accommodations, Expenses - Takeda
 
Petar Pop-Damkov
Employment - Takeda
Stock and Other Ownership Interests - Takeda
 
Koji Tamada
Leadership - Noile-Immune Biotech Inc.
Stock and Other Ownership Interests - Noile-Immune Biotech Inc.
Honoraria - Abbvie; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Gilead Sciences K.K.; Kyowa Kirin; Merck; Merck Sharp & Dohme; Novartis; Ono Pharmaceutical; Takeda
Consulting or Advisory Role - Astellas Pharma; Daiichi Sankyo; Kyowa Kirin; Ono Pharmaceutical
Research Funding - Chugai Pharma; Noile-Immune Biotech Inc.
 
Takafumi Koyama
Honoraria - Chugai Pharma; Sysmex
Consulting or Advisory Role - Amgen
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo RD Novare (Inst); Lilly (Inst); Novartis (Inst); PACT Pharma (Inst); Pfizer (Inst); Takeda (Inst); Zymeworks (Inst)